Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of the study is to acquire a database of Single Photon Emission Computed Tomographic (SPECT) studies of the brains of normal human subjects in resting and concentrating states. The database will provide a basis for subsequent investigation of meaningful brain differences between clinical and normal subject groups
See brief summary.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy brain subjects | The study seeks to recruit 100 normal, healthy brain subjects between ages 10 and 90 for SPECT brain imaging. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Baseline SPECT image | For the baseline resting study with adult subjects approximately 20 milliCuries of Tc-99m-hexamethylpropylene amine oxime (HMPAO, commercially marketed by Amersham Pharmaceuticals under the trade name Ceretec) will be injected after the initial equilibration period. Ceretec is an FDA-approved functional brain imaging radiopharmaceutical currently widely commercially available. | 24 hour assessment and data may be presented up to 10 years later as part of a normative database |
| Measure | Description | Time Frame |
|---|---|---|
| Concentration SPECT image | For the concentration study the subject will start the Conner's Continuous Performance Task, a 15-minute computer-administered test of attention, subsequent to the accommodation period. Three minutes into task performance HMPAO will be injected through the catheter with attention to minimal disruption of the subject's attention task. The subject will proceed to completion of the attention task. |
Not provided
Inclusion Criteria:
The study seeks to recruit 100 normal human subjects between ages 10 and 90 for SPECT brain imaging. Subjects will initially be screened for psychiatric and other major illnesses with a screening questionnaire; they will also be given a standard DSM-4 computer-administered questionnaire (The DISC for children and teens and the SCID for adults). They will also meet individually with a psychiatrist or psychological assistant for a screening interview.
Exclusion Criteria:
Not provided
Not provided
The study seeks to recruit 100 subjects between ages 10 and 90 for SPECT brain imaging.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Daniel G Amen, MD | Amen Clinics, Inc. | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Amen Clinics, Inc. | Newport Beach | California | 92660 | United States |
Not provided
Not provided
Not provided
Not provided
| 24 hour assessment and data may be presented up to 10 years later as part of a normative database |